Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases

Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases

Yayi He,1,* Wenwen Sun,2,* Yan Wang,3,* Shengxiang Ren,1 Xuefei Li,3 Jiayu Li,3 Christopher J Rivard,4 Caicun Zhou,1 Fred R Hirsch4 1Department of Oncology, Shanghai Pulmonary Hospital, 2Clinic and Research Center of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital...

Full description

Bibliographic Details
Main Authors: He YY, Sun WW, Wang Y, Ren SX, Li XF, Li JY, Rivard CJ, Zhou CC, Hirsch FR
Format: Article
Language:English
Published: Dove Medical Press 2016-04-01
Series:OncoTargets and Therapy
Subjects:
Erlotinib
Pemetrexed
Lung adenocarcinoma
EGFR
Asymptomatic brain metastases
Online Access:https://www.dovepress.com/comparison-of-erlotinib-and-pemetrexed-as-second-third-line-treatment--peer-reviewed-article-OTT

Internet

https://www.dovepress.com/comparison-of-erlotinib-and-pemetrexed-as-second-third-line-treatment--peer-reviewed-article-OTT

Similar Items